Tadalafil

Tadalafil is used to treat pulmonary hypertension and vasculogenic impotence, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Nov 21, 2003, and the first generic was approved May 22, 2018. FDA's Orange Book lists 120 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $109 million on Tadalafil across 379,000 claims for 90,000 beneficiaries.

Tadalafil is available as 125 NDCs from 23 manufacturers (120 generic, 5 brand), with NADAC prices from $0.10 to $67.34 per EA — the most expensive product costs about 653× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.